Award
NIH Reporter #1R01DK148498-01
Chemical Activation of Beta-Cell BiP for Treatment of Type 2 Diabetes
Recipient
University of Michigan at Ann Arbor
Award Amount
$810,438.00
Ceiling
$810,438.00
Awarded
July 24, 2026
Identifier
1R01DK148498-01
NIH awarded a grant to the University of Michigan at Ann Arbor to develop therapeutic agents targeting Beta-Cell BiP activation for Type 2 Diabetes treatment, focusing on improving insulin production and reducing ER stress.
Description
This NIH grant project aims to develop small molecule modulators to activate Beta-Cell BiP to improve proinsulin folding efficiency, reduce ER stress, and enhance insulin secretion as a treatment for Type 2 Diabetes. The project involves chemical biology, cell biology, and insulin biology, including in vitro and in vivo testing, drug derivatization, and targeted delivery to beta cells.